Brought to you by 
Kite gets rights to Sangamo's zinc finger nuclease platform; could pay $3bn
22 Oct 2021
Executive Summary
Gilead Sciences Inc. division Kite Pharma Inc. licensed exclusive rights to use Sangamo Therapeutics Inc.’s zinc finger nuclease (ZFN) technology for the development of new cell therapies for cancer.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Immuno-Oncology
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Kite gets rights to Sangamo's zinc finger nuclease platform; could pay $3bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice